关键词: 宏基因组二代测序技术, 肺孢子菌肺炎, 肾脏疾病, 免疫抑制剂

Abstract: Ｏｂｊｅｃｔｉｖｅ：To evaluate the diagnostic value of metagenomic nextgeneration sequencing (mNGS) for pneumocystis pneumonia (PCP) in patients with kidney disease receiving immunosuppressive therapy.Ｍｅｔｈｏｄｏｌｏｇｙ：37 cases of clinical diagnosed PCP patients after immunosuppressant therapy were selected,25 cases with pneumonia caused by other pathogens were selected as  control group. mNGS was used to analyze the pathogen types and sequences in peripheral blood samples to evaluate the detection efficiency to PCP. Efficacy of mNGS and traditional clinical diagnosis (fungal G test combined with lactate dehydrogenase detection) of PCP were compared.
Ｒｅｓｕｌｔｓ：37 peripheral blood samples were collected from 37 clinical diagnosed PCP patients,of which 35 were identified by mNGS,with a sensitivity of 9459％,specificity of 100％. 31 patients were complicated with mixed infection,19 with cytomegalovirus infection and 8 with bacterial infection. The sensitivity of fungal G test combined with lactate dehydrogenase was 8919％,the specificity was 560％. Pneumocystis sequences were negative in all controls.Ｃｏｎｃｌｕｓｉｏｎ：mNGS has obvious advantages over the traditional method of diagnosing PCP. It has the characteristics of accuracy,simplicity and noninvasiveness,and is of great value for the early diagnosis of PCP.